Table 1 Baseline preoperative characteristics and descriptive statistics of participants (No. = 180; mean (SD), [range]).

From: Prevalence and predictors of being lost to follow-up after transurethral resection of the prostate

 

Overall

LTF

−LTF

p-value (F)*

No. of patients (%)

180 (100)

55 (30.5)

125 (69.5)

 

Age (years)

69.8 (8.5)

65.8 (9.4)

71.6 (7.4)

<0.001 (16.4)

 

[48–87]

[48–87]

[55–87]

 

BMI [kg/m2]

26.1 (4.1)

25.8 (3.5)

26.3 (4.3)

0.55 (0.35)

 

[18.4–42.9]

[19.5–33.6]

[18.4–42.9]

 

CCI categorized [No. (%)]

   

0.73 (X2 = 0.11)

    0

75 (41.6)

24 (43.5)

51 (40.6)

 

    ≥1

105 (58.4)

31 (56.5)

74 (59.4)

 

Educational Status [No. (%)]

   

0.007 (X2= 7.2)

    Primary/ Secondary school

82 (45.5)

34 (61.7)

48 (38.4)

 

    High school/University

98 (54.5)

21 (38.3)

77 (61.6)

 

Marital Status [No. (%)]

   

0.038 (X2 = 4.30)

    Single

29 (16.2)

14 (25.5)

15 (12.1)

 

    Married

151 (83.8)

41 (74.5)

110 (87.9)

 

Psychiatric disorders [No. (%)]

4 (2.2)

1 (1.8)

3 (2.4)

0.32 (X2 = 1.01)

Distance traveled (km)

23.5 (77.7)

34.1 (98.3)

19.9 (51.2)

0.26 (1.23)

 

[0.3–603]

[0.7–603]

[0.3–465]

 

POC [No. (%)]

62 (34.4)

22 (40.4)

40 (31.8)

0.29 (X2 = 1.08)

Time of POC (months)

8.7 (8.8)

7.7 (3.0)

9.3 (10.9)

0.53 (0.39)

 

[2–60]

[2–14]

[3–60]

 

Total IPSS score

17.6 (4.4)

17.3 (5.5)

17.9 (5.1)

0.21 (1.51)

 

[12–33]

[12–33]

[12–31]

 

PSA (ng/ml)

4.2 (3.8)

3.5 (2.5)

4.4 (4.3)

0.17 (1.89)

 

[0.1–8.4]

[0.3–5.2]

[0.1–8.4]

 

Prostate Volume (ml)

79.6 (45.7)

71.1 (35.5)

83.1 (49.0)

0.15 (2.09)

 

[14–160]

[14–141]

[15–160]

 

Flow Max (ml/sec)

13.9 (19.1)

16.1 (25.4)

12.7 (14.8)

0.44 (0.58)

 

[2.1–52.0]

[2.1–52.0]

[2.1–42.0]

 
  1. Keys: LTF = Lost to follow up; BMI = body mass index; CCI = Charlson Comorbidity Index; POC = Preoperative catheterization; PSA = Prostate Specific Antigen; IPSS = International Prostatic Symptoms Score.
  2. *P value according to chi-square test or analysis of variance (ANOVA), as indicated.